Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0001562180-25-004722
Filing Date
2025-06-11
Accepted
2025-06-11 17:15:50
Documents
1
Period of Report
2025-06-10

Document Format Files

Seq Description Document Type Size
1 PRIMARY DOCUMENT primarydocument.html 4  
1 PRIMARY DOCUMENT primarydocument.xml 4 6571
  Complete submission text file 0001562180-25-004722.txt   7991
Mailing Address 245 FIRST STREET CAMBRIDGE MA 02142
Business Address 245 FIRST STREET CAMBRIDGE MA 02142 617-871-2098
Akebia Therapeutics, Inc. (Issuer) CIK: 0001517022 (see all company filings)

EIN.: 208756903 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address C/O AKEBIA THERAPEUTICS, INC. 245 FIRST STREET CAMBRIDGE MA 02142
Business Address
Wolf Myles (Reporting) CIK: 0001808317 (see all company filings)

Type: 4 | Act: 34 | File No.: 001-36352 | Film No.: 251040881